Insiders Advisor
  • Stocks
  • World News
  • Business
  • Politics
  • Stocks
  • World News
  • Business
  • Politics

Insiders Advisor

World News

GSK to cap out-of-pocket inhaler costs in US

by March 21, 2024
March 21, 2024
GSK to cap out-of-pocket inhaler costs in US

British pharmaceutical giant GSK said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for eligible patients in the United States, following similar moves by two of its rivals.

GSK said the decision will take effect by Jan. 1, 2025.

The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients whose monthly costs currently exceed $35.

US lawmakers in January had criticized the top four inhalers manufacturers — AstraZeneca, Boehringer, Teva Pharmaceuticals and GSK — over high prices, and launched an investigation to look into the prices at which these were sold in the US versus other countries.

The lawmakers claimed in the letter sent to the four companies in January that GSK’s Advair HFA costs $319 in the United States but $26 in the United Kingdom.

The company said it has recently reduced the wholesale acquisition cost for Advair Diskus by an average of 50% and Advair HFA by an average of 20%.

Anglo-Swedish drugmaker AstraZeneca and Germany’s Boehringer Ingelheim said earlier this month they would cap out-of-pocket costs for their inhaled respiratory products at $35 per month in the US from June. – Reuters

previous post
Reddit prices IPO at top of indicated range to raise $748 million
next post
Fed sees three rate cuts in 2024 but a more shallow easing path

Related Posts

Biden wins Michigan primary but thousands of Democrats...

February 28, 2024

Donald Trump joins TikTok and rapidly wins three...

June 3, 2024

Sports and music lessons for China’s kids in...

March 13, 2024

ECB keeps rates on hold but acknowledges some...

March 7, 2024

New Zealand scraps world-first ban on tobacco sales...

February 27, 2024

US trade chief looks for incremental reform at...

February 15, 2024

J.K. Rowling will not face action under Scottish...

April 3, 2024

Global child mortality rates dropped in 2022 but...

March 13, 2024

More handshakes, fewer rallies as Biden 2024 campaign...

March 27, 2024

Mainland Chinese surge into Hong Kong property after...

March 19, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Latest News

    • Key Republican vows Israel has ‘bipartisan support’ in Congress amid worsening Iran conflict

      June 18, 2025
    • Thune warns Iran should return to negotiating table ‘if they’re smart’

      June 18, 2025
    • Alleged Chinese scheme to influence 2020 election for Biden being probed by FBI, Senate Judiciary Committee

      June 17, 2025
    • Homeland Security Secretary Kristi Noem hospitalized after allergic reaction

      June 17, 2025
    • Key Republican calls for emergency funding to Israel amid worsening Iran conflict

      June 17, 2025
    • American citizen killed in Russian attack on Kyiv, State Department confirms

      June 17, 2025

    Categories

    • Business (1,268)
    • Politics (6,012)
    • Stocks (904)
    • World News (457)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: insidersadvisor.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 insidersadvisor.com | All Rights Reserved